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Abstract
Background: Studies have partly demonstrated the clinical validity of Ki-67 as a predictive marker in the
neoadjuvant setting, but the question of the best cut-off points as well as the importance of this marker as a
prognostic factor in partial responder/non-responder groups remains uncertain.
Methods: One hundred twenty patients diagnosed with invasive breast cancer and treated with neoadjuvant
chemotherapy (NAC) between 2002 and 2013 were retrospectively recruited to this study. The optimal cut-off value for
Ki-67 labeling index (LI) to discriminate response to treatment was assessed by receiver operating characteristic (ROC)
curve analysis. Kaplan-Meier curve estimation, log-rank test and cox regression analysis were carried out to reveal the
association between Ki-67 categories and survival (DMFS = Distant metastases-free survival, OS = Overall survival).
Results: Twenty three out of 120 patients (19.2%) achieved pathologic complete remission (pCR), whereas partial
remission (pPR) and no response (pNR) to neoadjuvant chemotherapy (NAC) was detected in 60.8% and 20.0%,
respectively. The distribution of subtypes showed a significant difference in pathological response groups (p < 0.001).
Most of the TNBC cases were represented in pCR group.
The most relevant cut-off value for the Ki-67 distinguishing pCR from pNR cases was 20% (p = 0.002). No significant
threshold for Ki-67 was found regarding DMFS (p = 0.208). Considering OS, the optimal cut-off point occurred at 15%
Ki-67 (p = 0.006). The pPR group represented a significant Ki-67 threshold at 30% regarding OS (p = 0.001). Ki-67 and
pPR subgroups were not significantly associated (p = 0.653). For prognosis prediction, Ki-67 at 30% cut-off value (p = 0.
040) furthermore subtype (p = 0.037) as well as pathological response (p = 0.044) were suitable to separate patients into
good and unfavorable prognosis cohorts regarding OS. However, in multivariate analyses, only Ki-67 at 30% threshold
(p = 0.029), and subtype (p = 0.008) were independently linked to OS.
Conclusions: NAC is more efficient in tumors with at least 20% Ki-67 LI. Both Ki-67 LI and subtype showed a significant
association with pathological response. Ki-67 LI represented independent prognostic potential to OS in our
neoadjuvant patient cohort, while pathological response did not. Additionally, our data also suggest that if a tumor is
non-responder to NAC, increased Ki-67 is a poor prognostic marker.
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Background
Breast cancer is the most common malignant tumor
among women all around the industrialized world [1].
Proliferation is an essential characteristic of all cancer
types, including breast cancer [2]. The proliferation
activity of different tumors assessed with immunohisto-
chemical detection of the cell-cycle specific antigen Ki-
67 has been extensively studied in the last decade. Many
studies have shown that Ki67 expression is a useful
prognostic factor in breast cancer [3, 4]. Criscitiello et al.
reported that Ki67 expression can identify a subset of
patients among Luminal-B and node positive breast can-
cer cases who could benefit from addition of adjuvant
chemotherapy to hormone therapy [5]. Contradicting
this finding, Andre F. et al. reported that in the adjuvant
setting Ki67 staining lacks analytical validity, moreover,
no robust evidence indicates that Ki-67 staining predicts
the efficacy of adjuvant chemotherapy [6]. Assessment of
cellular proliferation by Ki-67 expression is not recom-
mended in routine pathological evaluation by either
International Ki-67 in Breast Cancer Working Group of
the Breast International Group and North American
Breast Cancer Group or the American Society of Clinical
Oncology (ASCO) given the fact that it is not totally
clear how Ki-67 measurements and thresholds could in-
fluence clinical decisions [7].
Nowadays neoadjuvant chemotherapy (NAC) has be-
come an accepted therapy choice, even in early stage
breast cancers. In the last few years several research stud-
ies have focused on the prognostic and predictive value of
Ki-67 expression in neoadjuvant settings [8–10]. The
International Ki-67 in Breast Cancer Group created guide-
lines for the assessment of Ki-67 with recommendations
on pre-analytical and analytical procedures, as well as on
interpretation, scoring, and data handling [11].
Achieving pathologic complete remission (pCR) re-
mains a subject of controversy in terms of definition and
its evaluation methods. The predictive value of pCR in
relation to patient outcome in various breast cancer bio-
logical subtypes has been under debate. pCR has
strongly predicted improved survival in triple negative
breast cancer (TNBC) and HER2-enriched subgroups,
while there are contradictory data related to the luminal
subtypes [12, 13].
Even if significant efforts are currently made to select
the group of patients who will benefit from NAC, there
are no clear genomic markers that can predict the re-
sponse rate [14]. There are contradictory data about Ki-
67 as a predictive factor [8, 9] for response to NAC and
there are several questions to be answered, such as the
standardization of the methodology used for Ki-67 de-
tection, or how Ki-67 expression in core biopsies is rep-
resentative of the whole tumor. It is becoming clear that
there is an urgent need for standardized Ki-67
diagnostics or a need for use of other markers associated
with cell proliferation. Klauschen et al. reported that the
computer assisted Ki-67 scoring approach correlated
with the clinical endpoints [15]. Balmativola et al. found
that 18% threshold of Ki-67 positive cells accurately dis-
criminated the pCR and non-pCR patient groups [8]. In
a recent study by Magbanua et al. it is nicely presented
that in addition to single-gene studies, genomic ap-
proaches are needed to maximize the discovery of useful
classifiers and druggable targets in the NAC setting [14].
The majority of previous research studies have focused
mostly on the group of patients presenting pCR. Only a
few studies have investigated the value of KI-67 in non-
responders to NAC [8]. Even though partial responders
to NAC represent the largest group with a very hetero-
geneous population, and although patients with minimal
residual cancer burden after neoadjuvant chemotherapy
often have the same excellent prognosis as patients who
achieve pCR, there are very few studies offering add-
itional information about the likelihood of partial re-
sponse to NAC [16, 17]. Until this will happen, we need
to investigate more clearly the relationship between pre-
therapeutic Ki-67 expression and response to neoadju-
vant chemotherapy.
Our aim in this study was to find optimal cut-off
values for Ki-67 expression that best correlates with re-
sponse rates to NAC and with DMFS (distant
metastasis-free survival) as well as with OS (overall sur-
vival). We also investigated the association between Ki-
67, subtype and pathological response, as well as the
prognostic potential of Ki-67 in partial responder pa-
tients. Furthermore, the prognosis prediction potential
of Ki-67 was correlated to that of the conventional clini-
copathological factors in multivariate analysis.
Methods
A total of 120 patients diagnosed with invasive breast
cancer and treated with NAC at Semmelweis University
in Hungary between 2002 and 2013 were retrospectively
recruited for this observational, cross-sectional cohort
study. Patients were enrolled only if they had completed
NAC, thereafter underwent surgery. The study was eth-
ically approved by the Semmelweis University Institu-
tional Review Board (SE-IKEB 120/2013).
The data recorded are partly presented in Table 1 and
were as follows:
a. age at diagnosis, clinical and pathologic tumor size
(cT and pT), nodal involvement (cN)
b. in the pre-treatment biopsy: histological type and
nuclear grade, Ki-67 LI, Estrogen Receptor (ER),
Progesterone Receptor (PgR), and human epidermal
growth factor receptor 2 (HER2) status (based on
Ács et al. Diagnostic Pathology  (2017) 12:20 Page 2 of 12
both immunostaining score and in situ hybridization
analysis for HER2 score 2 cases)
c. degree of response to therapy was categorized
following Pinder et al. [18] in the histological
sections of the post treatment surgical specimens as
follows: Pathologic complete response (pCR) was
defined as no residual invasive tumour and the
absence of any residual invasive tumor in the lymph
nodes. Partial response to therapy (pPR), either
<10% of tumour remaining (pPRi), or 10–50%
tumour remaining (pPRii), or >50% of tumor
remaining but some evidence of response to therapy
is present (pPRiii). Non responders (pNR) were
defined as no evidence of response to therapy,
d. Surrogate molecular subtypes were defined based
on the 2013 St. Gallen Consensus Conference
recommendations as Luminal-A, Luminal-B/
HER2-, Luminal-B/HER2+, HER2+ and triple
negative categories [19, 20].
Immunohistochemical analysis
ER, PgR, HER2 status and Ki-67 LI were evaluated in the
pre-treatment core biopsy specimens and in case of non
pCR, on the surgical specimens as well, by immunohisto-
chemistry (IHC). All immunohistochemical analyses were
carried out at the 2nd Dept. of Pathology, Semmelweis
University, Hungary with automated immunostainer sys-
tem (Ventana Benchmark XT, Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s in-
structions, using the following antibodies: 1:200 anti-ER
(clone 6 F11), 1:200 anti-PgR (clone 312) and 1:150 anti-
HER2 (clone CB11) antibodies purchased from Novocas-
tra Laboratories Ltd (Newcastle upon Tyne, UK), and
1:100 anti-Ki67 (clone MIB1) antibody purchased from
DAKO Gmbh (Hamburg, Germany). The antigen retrieval
method was performed in the immunostainer with CC1
antigen retrieval solution on pH9 at 42 °C for 30 min.
Table 1 Clinicopathological data of analyzed cases
Number of
cases
Total
%
Valid
%
Age 40≥ 29 24.2 24.2
40 < 91 75.8 75.8
cT T1 19 15.8 15.8
T2 73 60.8 60.8
T3 15 12.5 12.5
T4 13 10.8 10.8
pT pT0 20 16.7 18.7
pT1 40 33.3 37.4
pT2 34 28.3 31.8
pT3 9 7.5 8.4
pT4 4 3.3 3.7
Unknown 13 10.8
cN N0 46 38.3 40.4
N1 55 45.8 48.3
N2 9 7.5 7.9
N3 4 3.3 3.5
Nx 6 5.0
pN pN0 51 42.5 48.1
pN1 36 30 33.9
pN2 13 10.8 12.3
pN3 6 5 5.7
Nx 14 11.7
Grade 1 1 0.8 0.9
2 46 38.3 41.8
3 63 52.5 57.3
Unknown 10 8.3
ER status Positive 80 66.7 66.7
Negative 40 33.3 33.3
PgR status 20% > 8 6.7 6.7
20%≤ 49 40.8 41.2
Negative 62 51.7 52.1
Unknown 1 0.8
HER2 status Positive 41 34.2 34.2
Negative 79 65.8 65.8
Histological type Lobular 6 5.0 5.1
IBC NOS 112 93.3 94.9
Other/Unknown 2 1.7
Molecular
subtype
Luminal A 15 12.5 12.5
Luminal B/HER2- 38 31.7 31.7
Luminal B/HER2
+
27 22.5 22.5
HER2+ 14 11.7 11.7
Triple-negative 26 21.7 21.7
Table 1 Clinicopathological data of analyzed cases (Continued)
Response Complete 23 19.2 19.2
Partial 73 60.8 60.8
Non-responder 24 20.0 20.0
Antracyclines Yes 88 73.3 73.3
No 32 26.7 26.7
Taxanes Yes 99 82.5 82.5
No 21 17.5 17.5
Platinum Yes 31 25.83 25.83
No 89 74.16 74.16
Trastuzumab Yes 12 10.0 10.0
No 108 90.0 90.0
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The cut-off value for ER and PgR positivity was 1%
positive tumor cells with nuclear staining. Hormone
receptor (HR) negativity was defined as being negative
for both ER and PgR. HER2 IHC positivity was de-
fined as score 3+ complete, strong membrane staining
in >10% of tumor cells. For IHC 2+ samples, fluores-
cent in situ hybridization (FISH) was performed to
confirm gene amplification by using Zytovision
ERBB2/CEN17 dual FISH probes. HER2 status was
defined according to the ASCO/CAP guideline valid
at the time of diagnosis (ASCO/CAP guideline 2007
and ASCO/CAP guideline 2013) [21, 22].
Ki-67 was scored as the percentage of positive tumor
cell nuclei by counting a range of 400–500 cells (de-
pending on the cellularity of the specimen), including
also hot spot areas. The optimal cut-off value for Ki67
was defined by statistical analysis; however we also ap-
plied the 20 and 30% threshold values as mostly recom-
mended cut-off scores in the literature.
Clinical outcome assessment
Overall survival was defined as the elapsed time from
the date of diagnosis of the tumor by core biopsy to the
date of death, or when patients were last censored if still
alive. DMFS was defined as time from the date of pri-
mary diagnosis to the occurrence of first distant metas-
tases. All patients were followed-up until the date of
death or when censored at the date April 30, 2015 (me-
dian follow up time for OS and DMFS was 60.5 and
59 months, respectively).
Statistical analysis
All analyses were carried out using SPSS version 22.0
statistical software (SPSS Inc, Chicago, IL, USA). Differ-
ences in the distribution of characteristics between the
parameters of patients with pCR or pPR and patients
with pNR were evaluated using two-sided Fisher’s Exact
Test. Two-sided Mann-Whitney-Wilcoxon test was used
to define age distributions in pCR vs. pNR and vs. pPR.
The optimal cut-off value for Ki-67 percentage to dis-
criminate response to treatment was assessed by receiver
operating characteristic (ROC) curve analysis. To iden-
tify the optimal Ki-67 threshold for NAC, only pCR and
pNR cases were involved in ROC analyses, because pPR
status is considered as a soft endpoint. Kaplan-Meier
curve estimation, log-rank test and Cox regression ana-
lysis were carried out to analyze the association between
Ki-67 categories and DMFS or OS. P values ≤0.05 were
considered to be statistically significant.
Results
Baseline clinical and pathological data
Hundred and twenty patients met the inclusion criteria
and their data were used in this study.
Mean patient age was 50.6 years (range, 29–74 years).
The majority of patients (59.6%) had node-positive dis-
ease and cT2 tumors (60.8%). Tumors were ER-positive
in 66.7% of cases and presented PgR positivity >20.0% in
41.2% of the analyzed samples. In 34.2% of cases HER2
positivity was detected. Of the 120 tumors, 12.5% were
of Luminal-A, 31.7% of Luminal-B/HER2 negative,
22.5% of Luminal-B/HER2 positive, 11.7% of HER2+ and
21.7% of TNBC subtype (Table 1).
Twenty three out of 120 patients (19.2%) achieved
pathologic complete remission (pCR), 73 (60.8%) showed
partial remission (pPR), whereas no response to NAC
(pNR) was detected in 24 cases (20.0%).
In the group of patients who obtained pPR, residual
tumor was detected in lymph nodes only in 7 patients
(9.6%), major response (>90% tumor regression) to
NAC was observed in 8 cases (11.0%), a response rate
between 50 and 90% was detected in 26 cases
(35.6%), whereas a response rate <50% was observed
in 32 cases (43.8%).
Non-responder patients (pNR, mean age: 56) showed
significant difference (p = 0.008) in age compared to pa-
tients achieving pathologic complete response (pCR,
mean age: 46). This association between pNR patients’
age and pCR patients’ age was mainly confined to the
HR+ patient population.
Significant difference in HR status was observed be-
tween the pCR, pPR and pNR populations (p < 0.001):
approximately three-quarters of the samples within
the pCR group were HR negative as contrasted to the
pPR and pNR groups, in which cases the proportion
of HR+ samples was more than 3-times higher
(Table 2).
Table 2 Association between age, hormone receptor positivity and therapy response
Therapy response
category
N HR status (%) p1 Average age at diagnosis (year ± SD) p2
HR+ HR− HR+ HR− all
pCR 23 5 (21.7) 18 (78.3) <0.001 44.2 ± 12.6 46.4 ± 13.8 46.0 ± 13.3 0.008
pPR 73 55 (75.3) 18 (24.7) 50.0 ± 11.0 52.3 ± 12.8 50.4 ± 11.4
pNR 24 20 (83.3) 4 (16.7) 55.9 ± 10.7 53.3 ± 14.5 55.6 ± 11.0
HR – hormone receptor positive (+) or negative (−)
1two-sided Fisher’s exact test; 2Kruskal-Wallis H-test with Dunn’s posthoc (multiple comparison) test for all samples without regarding the HR status
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Defining cut-off points for Ki-67expression in the pCR and
pNR groups
ROC curve analysis was used in order to identify the op-
timal cut-off value of Ki-67 expression that could best
predict response to NAC (Fig. 1a). The optimal Ki-67
cut-off value was 20% for distinguishing pCR from pNR
patient cases (n = 47, AUC 0.767, sensitivity: 95.7%, spe-
cificity: 54.3%, p = 0.002). (Fig. 1a).
Defining cut-off points for Ki-67 expression based on
Survival (DMFS and OS)
We also investigated the optimal threshold values for
Ki-67 regarding DMFS and OS. Based on DMFS, we
were not able to detect a statistically significant cut-off
value for Ki-67. The most relevant cut-off value was 20%
(n = 120, AUC 0.591, sensitivity: 82.2%, specificity 35.7,
p = 0.208) (Fig. 1b). On the basis of OS data, the optimal
cut-off point occurred at 15% for Ki-67 (n = 120, AUC
0.708, sensitivity: 92.3%, specificity 29.6, p = 0.006)
(Fig. 1c).
Association between Ki-67, Subtype and Pathological
Response
Pathological response and Ki-67 at investigated
thresholds represented a significant association (Ki-67
15% p = 0.001, Ki-67 20% p = 0.010, Ki-67 30% p =
0.018). The proportion of Ki-67 low cases among
non-responders was significantly higher compared to
pPR and pCR cases (Additional file 1A). The distribu-
tion of subtypes showed a significant difference in
pathological response groups (p < 0.001). Most of the
TNBC cases were represented in pCR group, while
luminal-A cases mainly occurred in pPR and pNR
groups (Additional file 1B). The Ki-67 expression at
any investigated cut-off points and subtypes also rep-
resented a significant correlation (p < 0.001 for all
comparisons). Luminal-A subtype showed low Ki-67,
while TNBC and HER2+ cases mostly had high Ki-67
(Additional file 1C). The association between Ki-67,
subtype and pathological response was also investi-
gated without Luminal-A cases, because NAC is not
generally recommended in this subtype due to the
high rate of pNR status in contrast with the favorable
prognosis. Excluding Luminal-A cases, Ki-67 at any
thresholds and pathological response did not show
any significant association (Ki-67 15% p = 0.068, Ki-67
20% p = 0.122, Ki-67 30% p = 0.140) (Additional file
2A). Furthermore, Ki-67 expression at any investi-
gated cut-off points also did not represent any signifi-
cant linkage with subtypes (Ki-67 15% p = 0.410, Ki-
67 20% p = 0.158, Ki-67 30% p = 0.173) (Additional file
2C). In contrast to this, subtypes were significantly
linked to the pathological response groups (p < 0.001).
The vast majority of Luminal-B cases were in pPR
and pNR groups, while TNBC cases mostly occurred
in pCR subgroup (Additional file 2B).
Prognostic potential of Ki-67 status, Subtype and
Pathological Response (DMFS and OS)
Neither Ki-67 at any thresholds nor subtype and not
even pathological response were suitable to distinguish
patient cohorts with different DMFS (Ki-67 15% p =
0.391, Ki-67 20% p = 0.185, Ki-67 30% p = 0.566, subtype
p = 0.771, pathological response p = 0.280). Regarding
OS Ki-67 at 15% (p = 0.263) and at 20% threshold failed
(p = 0.131), but Ki-67 at 30% cut-off value (p = 0.040)
furthermore subtype (p = 0.037) as well as pathological
response (p = 0.044) were suitable to separate patients
into good and unfavorable prognosis cohorts (Fig. 2).
When Luminal-A cases were excluded, neither Ki-67 at
any cut-off points nor subtype not even pathological re-
sponse were suitable to perform statistically significant
splitting of our cohort into 2 patients’ group with differ-
ent DMFS (Ki-67 15% p = 0.426, Ki-67 20% p = 0.179,
Ki-67 30% p = 0.642, subtype p = 0.488, pathological re-
sponse p = 0.222,) or with different OS (Ki-67 15% p =
0.975, Ki-67 20% p = 0.518, Ki-67 30% p = 0.158, subtype
p = 0.072, pathological response p = 0.058, Additional
file 3). We also investigated the utility of Ki-67 at 15,
20 and 30% thresholds as potential independent pre-
dictor of DMFS and OS adjusted by age, pathological
response, hormone receptor status, subtypes, histo-
logical grade, lymph node, cT and pT status. Neither
Ki-67 at any thresholds nor any other clinicopatho-
logical factors except pT status (p = 0.029) showed an
independent association with DMFS (Table 3). How-
ever, Ki-67 at 30% threshold (p = 0.029) and subtype
(p = 0.008) were independently linked to OS (Table 3).
Without Luminal-A cases, Ki-67 at 30% cut-off point
(p = 0.038) and subtype (p = 0.009) represented also an
independent association with OS (Table 3).
Ki-67 expression in the partial responder group
The prognostic potential of Ki-67 was also investi-
gated in pPR subgroup that represents a heteroge-
neous group with a response rate to NAC between 10
and 90%. Attempting to find the most relevant
threshold for Ki-67, we could conclude that, the best
cut-off value in pPR group based on DMFS was 20%
(n = 73, AUC 0.683, sensitivity: 82.4%, specificity
41.5%, p = 0.055, Fig. 3a), and 30% based on OS (n =
73, AUC 0.808, sensitivity: 92.2%, specificity 52.6, p =
0.001, Fig. 3b). No significant association was found
between Ki-67 and pPR subgroups (pPRi, pPRii,
pPRiii; p = 0.653)
For prognosis prediction, neither Ki-67 at any cut-off
value (Ki-67 20% p = 0.233, Ki-67 30% p = 0.336), nor
subtype (p = 0.218) not even pPR subgroups (p = 0.669)
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were able to distinguish patient cohorts with different
DMFS. Regarding OS, pPR subgroups (p = 0.590) and
Ki-67 at 20% threshold failed (p = 0.095), but Ki-67 at
30% cut-off point (p = 0.037) and subtype (0.015) were
suitable to separate patients into good and unfavorable
prognosis cohorts (Fig. 4).
Discussion
Neoadjuvant systemic therapy is being increasingly
used in the treatment of early stage breast cancer.
Despite several classification systems developed for
the assessment of pathologic response to NAC there
is a current lack in uniformity regarding the defin-
ition of pathologic complete response [23, 24]. Since
pCR is considered as the primary endpoint for re-
sponse to chemotherapy, a majority of studies focus
attention on pCR cases, while detailed analyses of
partial responder or non-responder cases are relatively
rare [8]. One of the hot topics in neoadjuvant therapy
of breast cancer patients involves the question of reli-
able prognostic and predictive markers. A high num-
ber of studies have been conducted on the
proliferation marker Ki-67, but due to the many con-
troversies and debated issues this marker has not
been fully integrated into clinical decision making.
Some of the questions about the performance of Ki-
67 as well as NAC in daily clinical practice concern
the issue of cut points for Ki-67 and its use as prog-
nostic or predictive marker. Different cut points are
described, with values varying between 5 and 34%
[25], between 3 and 94% for pCR, and between 6 and
46% for DMFS [10, 26]. The 2013 St. Gallen consensus
recommended a Ki-67 cut-off value of 14% for the separ-
ation of luminal-A and B tumors, but in the footnote of
the respective table there was a note indicating 20% as
cut-off for “high” Ki67 LI. [19].
Our finding is in agreement with the results of Denkert
et al. according to which Ki-67 is a mixed prognostic and
predictive marker with its effect differing in opposite di-
rections as regards prognosis and prediction [27].
Our study revealed that a Ki-67 cut-off value of about
20% distinguished pCR from pNR cases, whereas pa-
tients exhibiting Ki-67 expression lower than 30% dem-
onstrated a higher chance of better overall survival.
Increased Ki-67 LI was linked to worse OS, meaning
that at least in some subgroups higher Ki-67 expression
was related to increased response to NAC and was also
Fig. 1 ROC curves to define optimal Ki-67 cut-off values for pathological
response (a), DMFS (b), OS (c). Green line represents the diagonal reference
line. Blue line corresponds to ROC curve. Red circles show the optimal cut-
off values based on the ROC curves
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associated with worse prognosis. These data may suggest
that if a tumor belongs to the group showing no re-
sponse to NAC, increased Ki-67 is a marker of poor
prognosis.
Denkert et al. also suggest that based on Ki-67 expres-
sion there are three different groups of tumors, such as
a group with low Ki-67 with good outcome, a group
showing high Ki-67 and good outcome and a third
*
*
*
*significant *significant
*significant
p=0.263
HR=2.273
CI=0.519-9.967
p=0.131
HR=2.960
CI=0.674-12.999
p=0.040
HR=3.423
CI=1.217-11.922
p=0.037
HR=1.544
CI=1.141-2.492
p=0.044
HR=2.096
CI=1.067-4.548
Fig. 2 Kaplan Meier plots of Ki-67, subtype and pathological response. Ki-67 at 30% cut-off value furthermore subtype and pathological response
were suitable to separate good and unfavorable patient cohorts regarding OS
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group with high Ki-67 linked to poor outcome [27].
There are relatively few studies addressing the question
of the role of Ki-67 in non-responder or pPR groups,
even if the majority of cases treated with NAC show
only partial response to chemotherapy.
In our study the majority of cases (60.83%) belonged
to the pPR group. Based on Ki-67 expression, this group
represented a mixture of tumors showing Ki-67 expres-
sion ranging from 1 to 100%. We analyzed whether the
group of patients showing a near complete pathologic
response (pPRi) showed higher Ki-67 expression com-
pared to pPRii and pPRiii. According to our findings,
there were no significant differences between these
groups regarding Ki-67 expression. Based on the pa-
tients’ follow-up data and using ROC analysis, the
most relevant prognostic cut-off value for the Ki-67
in the pPR group was 20% based on DMFS and 30%
based on OS.
Balmativola et al. analyzed markers of non-response to
NAC. Using ROC analysis, they identified a cut-off value
of 18% for Ki-67 that performed well in differentiating
the pNR and pCR + pPR categories [8].
In our study, Ki-67 expression was found to be
higher than 20% in all patients achieving pCR and
from the twenty-three pCR cases we detected distant
metastases in one case only. In our study a Ki-67 LI
of 20% was found capable of significantly distinguish-
ing between the pCR and pNR groups. Despite this
finding, however, it cannot be concluded that this is
the only or best cut-off value for Ki-67, since the
question then arises as to why a significant number
of tumors with a Ki-67 value higher than 20% did not
reach pCR.
Based on our results, both Ki-67 and subtype showed
significant association with pathological response. How-
ever, when Luminal-A cases were excluded, only subtype
and pathological response were significantly linked, so
we could conclude that subtype has a significant impact
on the association between Ki-67 LI and pathological re-
sponse. In contrast to this, both Ki-67 and subtype were
independently associated with OS, while pathological re-
sponse did not show significant relation with OS. Fur-
thermore, both Ki-67 and subtype were suitable to
separate pPR patients into good and unfavorable prog-
nosis cohorts.
Conclusion
Neoadjuvant chemotherapy is more efficient in tu-
mors presenting at least 20% Ki-67 expression. A cut-
off value of 20% distinguished pCR from pNR cases.
Increased Ki-67 LI was linked to worse OS, meaning
that at least in some subgroups higher Ki-67 expres-
sion is related to increased response to NAC and is
also associated with worse prognosis. Additionally,
our data also suggest that if a tumor is non-
responder to NAC, increased Ki-67 is a poor
prognostic marker. Moreover, Ki-67 represented inde-
pendent prognostic potential to OS, thus we can con-
clude that Ki-67 has potential utility in the clinical
management of breast cancer. However, we can also
state that Ki-67 in itself is not suitable to decide
whether a breast cancer patient should be treated
with NAC or not.
A
B
Fig. 3 ROC curves to define optimal Ki-67 cut-off values for DMFS,
OS in pPR group. Green line represents the diagonal reference line.
Blue line corresponds to ROC curve. Red circles show the optimal
cut-off values based on the ROC curves
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Limitations
The weakness of our retrospective study is the rela-
tively low number of cases, for which reason i.) we
could not define the optimal Ki-67 cut-off point for
each subtypes. ii.) We could not investigate whether
Ki-67 is suitable to predict pathological response in
each subtype. Similarly, we could not address the
question of the prognostic potential of Ki-67 for each
subtype in breast cancer patients who underwent neo-
adjuvant chemotherapy. iii.) We could not perform
treatment-stratified analyses.
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